Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 10/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.48 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777034 | 0.85 | KMO (0.61) | KMOMAP4K4HSD17B1HSD17B2KDM4E | |
| SCHEMBL4780344 | 0.85 | KMO (0.61) | KMOMAP4K4P4HA1MIFP4HTM | |
| SCHEMBL13731115 | 0.83 | P4HTM (0.64) | MAP4K4P4HA1MIFP4HTMKDM4E | |
| SCHEMBL11049832 | 0.81 | NOTUM (0.59) | KMOKDM4E | |
| SCHEMBL3355376 | 0.81 | KMO (1.00) | KMOAHRPPP1CAKDM4EALDH1A1 | |
| SCHEMBL4725410 | 0.80 | MAP4K4 (0.68) | KMOMAP4K4P4HA1MIFP4HTM | |
| SCHEMBL21552113 | 0.80 | EGLN1 (0.58) | KMOMAP4K4PPP1CAP4HTMPTGS2 | |
| SCHEMBL14742178 | 0.80 | KMO (0.59) | KMOMAP4K4PPP1CA | |
| Hydrochloric Acid SCHEMBL1939238 | 0.79 | KMO (0.97) | KMOAHRPPP1CAKDM4EALDH1A1 | |
| SCHEMBL11044929 | 0.79 | MAP4K4 (0.55) | KMOMAP4K4P4HA1MIFP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| WO-1984004302-A1 | SUBSTITUTED PICOLINIC ACIDS, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | KMO 360/4885MAP4K4 944/4885AHR 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.